I'm sure thousands of investors have come and gone with Vertex over the past 20+ years and many have lost a pile of money. But there is no reason that Vertex needs to pay back or make back the $5 billion you say has been invested in the company over the years. In fact, Vertex's balance sheet is looking great with more cash and assets on its books than liabilities (debt). And that will only get better as more revenue and profits roll in from Incivek and, soon, Kalydeco. Given the number of drugs Vertex is currently developing, I'm not surprised with its huge outlay for R&D. They are doing the right thing by plowing the profits back into the company. Share buybacks and dividends would be a bad sign.